
## Eder Lilia Romero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8626801/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. Colloids and Surfaces B: Biointerfaces, 2016, 139, 190-198.	2.5	118
2	Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. International Journal of Nanomedicine, 2013, 8, 3171.	3.3	89
3	On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Letters, 1999, 448, 193-196.	1.3	70
4	Nanotechnological approaches against Chagas disease. Advanced Drug Delivery Reviews, 2010, 62, 576-588.	6.6	64
5	Sunlight triggered photodynamic ultradeformable liposomes against Leishmania braziliensis are also leishmanicidal in the dark. Journal of Controlled Release, 2010, 147, 368-376.	4.8	61
6	Drug delivery systems against leishmaniasis? Still an open question. Expert Opinion on Drug Delivery, 2008, 5, 805-823.	2.4	60
7	Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. International Journal of Pharmaceutics, 2009, 380, 189-200.	2.6	57
8	Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent. International Journal of Pharmaceutics, 2006, 326, 160-168.	2.6	53
9	Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. Nanomedicine, 2015, 10, 465-481.	1.7	52
10	Ultradeformable archaeosomes as new topical adjuvants. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1319-1328.	1.7	51
11	Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. International Journal of Pharmaceutics, 2004, 278, 311-318.	2.6	50
12	Etanidazole in pH-sensitive liposomes: Design, characterization and in vitro/in vivo anti-Trypanosoma cruzi activity. Journal of Controlled Release, 2005, 103, 599-607.	4.8	46
13	In vitro phototoxicity of ultradeformable liposomes containing chloroaluminum phthalocyanine against New World Leishmania species. Journal of Photochemistry and Photobiology B: Biology, 2012, 117, 157-163.	1.7	46
14	Development and in vitro characterisation of a benznidazole liposomal formulation. International Journal of Pharmaceutics, 2002, 249, 89-99.	2.6	42
15	Increased brain radioactivity by intranasal 32P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. International Journal of Nanomedicine, 2012, 7, 1373.	3.3	40
16	Topical and mucosal liposomes for vaccine delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 356-375.	3.3	38
17	Curcumin-Loaded Lipid and Polymeric Nanocapsules Stabilized by Nonionic Surfactants: An <l>ln</l> <l>Vitro</l> and <l>In Vivo</l> Antitumor Activity on B16-F10 Melanoma and Macrophage Uptake Comparative Study. Journal of Biomedical Nanotechnology, 2011, 7, 406-414.	0.5	38
18	The anti MRSA biofilm activity of Thymus vulgaris essential oil in nanovesicles. Phytomedicine, 2019, 57, 339-351	2.3	34

Eder Lilia Romero

#	Article	IF	CITATIONS
19	Photodynamic ultradeformable liposomes: Design and characterization. International Journal of Pharmaceutics, 2007, 330, 183-194.	2.6	31
20	Selective cytotoxicity of PAMAM G5 core–PAMAM G2.5 shell tecto-dendrimers on melanoma cells. International Journal of Nanomedicine, 2012, 7, 4121.	3.3	31
21	Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. International Journal of Nanomedicine, 2011, 6, 2715.	3.3	30
22	Surviving nebulization-induced stress: dexamethasone in pH-sensitive archaeosomes. Nanomedicine, 2016, 11, 2103-2117.	1.7	30
23	Physicochemical characterization and cytotoxic studies of nonionic surfactant vesicles using sucrose esters as oral delivery systems. Colloids and Surfaces B: Biointerfaces, 2014, 117, 1-6.	2.5	29
24	Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa. Nanomedicine, 2017, 12, 1165-1175.	1.7	26
25	Structural features of ultradeformable archaeosomes for topical delivery of ovalbumin. Colloids and Surfaces B: Biointerfaces, 2014, 121, 281-289.	2.5	25
26	Ultradeformable Archaeosomes for Needle Free Nanovaccination with Leishmania braziliensis Antigens. PLoS ONE, 2016, 11, e0150185.	1.1	25
27	Superoxide dismutase in nanoarchaeosomes for targeted delivery to inflammatory macrophages. Colloids and Surfaces B: Biointerfaces, 2019, 179, 479-487.	2.5	24
28	Avoiding failed reconstitution of ultradeformable liposomes upon dehydration. International Journal of Pharmaceutics, 2009, 372, 184-190.	2.6	22
29	Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine. International Journal of Pharmaceutics, 2008, 360, 204-212.	2.6	21
30	Bacterioruberin from Haloarchaea plus dexamethasone in ultra-small macrophage-targeted nanoparticles as potential intestinal repairing agent. Colloids and Surfaces B: Biointerfaces, 2020, 191, 110961.	2.5	21
31	Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin. Current Pharmaceutical Design, 2015, 21, 2784-2800.	0.9	20
32	Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 213-219.	0.8	19
33	Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes. International Journal of Nanomedicine, 2014, 9, 3335.	3.3	19
34	Topical vaccination with super-stable ready to use nanovesicles. Colloids and Surfaces B: Biointerfaces, 2017, 152, 114-123.	2.5	19
35	Carrier Deformability in Drug Delivery. Current Pharmaceutical Design, 2016, 22, 1118-1134.	0.9	19
36	Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease. Human Vaccines and Immunotherapeutics, 2013, 9, 409-412.	1.4	18

Eder Lilia Romero

#	Article	IF	CITATIONS
37	Nebulizing novel multifunctional nanovesicles: the impact of macrophage-targeted-pH-sensitive archaeosomes on a pulmonary surfactant. Journal of Materials Chemistry B, 2017, 5, 8083-8095.	2.9	18
38	Sialic acid measurement by a modified Aminoff method: a time-saving reduction in 2-thiobarbituric acid concentration. Journal of Proteomics, 1997, 35, 129-134.	2.4	17
39	In vitro activity of Etanidazole against the protozoan parasite Trypanosoma cruzi. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 233-235.	0.8	15
40	Make It Simple: (SR-A1+TLR7) Macrophage Targeted NANOarchaeosomes. Frontiers in Bioengineering and Biotechnology, 2018, 6, 163.	2.0	15
41	Fast Biofilm Penetration and Anti-PAO1 Activity of Nebulized Azithromycin in Nanoarchaeosomes. Molecular Pharmaceutics, 2020, 17, 70-83.	2.3	14
42	Liposomal Benznidazole: A High-Performance Liquid Chromatographic Determination for Biodistribution Studies. Journal of Chromatographic Science, 2003, 41, 405-409.	0.7	13
43	Macrophage apoptosis using alendronate in targeted nanoarchaeosomes. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 160, 42-54.	2.0	12
44	The Intervention of Nanotechnology Against Epithelial Fungal Diseases. Journal of Biomaterials and Tissue Engineering, 2013, 3, 70-88.	0.0	12
45	Enhanced antimelanoma activity of methotrexate and zoledronic acid within polymeric sandwiches. Colloids and Surfaces B: Biointerfaces, 2014, 122, 19-29.	2.5	11
46	Novel imiquimod nanovesicles for topical vaccination. Colloids and Surfaces B: Biointerfaces, 2019, 174, 536-543.	2.5	8
47	Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. Pharmaceutics, 2021, 13, 1331.	2.0	7
48	The Anti-Inflammatory Effect of Nanoarchaeosomes on Human Endothelial Cells. Pharmaceutics, 2022, 14, 736.	2.0	6
49	Thymus vulgaris essential oilÂ+Âtobramycin within nanostructured archaeolipid carriers: A new approach against Pseudomonas aeruginosa biofilms. Phytomedicine, 2022, 102, 154179.	2.3	5
50	Liposome Elimination by Non-Phagocytic Cells of the Liver. Journal of Liposome Research, 2000, 10, 431-442.	1.5	3
51	Nanomedical Therapeutic and Prophylaxis Strategies Against Intracellular Protozoa in the Americas. , 2015, , 297-317.		2
52	Enhancing the anti-psoriatic activity of vitamin D3 employing nanostructured archaeolipid carriers. Journal of Drug Delivery Science and Technology, 2022, 73, 103455.	1.4	2
53	Nanotoxicity of Lipid-Based Nanomedicines. , 2018, , 133-165.		1
54	Preclinical autophagy modulatory nanomedicines: big challenges, slow advances. Expert Opinion on Drug Delivery, 2021, 18, 1415-1434.	2.4	1

#	Article	IF	CITATIONS
55	Toll like receptors agonists-based nanomedicines as veterinary immunotherapies. Precision Nanomedicine, 0, , .	0.4	1
56	Reparation of an Inflamed Air-Liquid Interface Cultured A549 Cells with Nebulized Nanocurcumin. Pharmaceutics, 2021, 13, .	2.0	1
57	Intracellular Bacteria and Protozoa. Fundamental Biomedical Technologies, 2011, , 745-811.	0.2	Ο
58	Core-Shell Nanotransporters for the Skin. , 2016, , 241-251.		0